panitumumab,bevacizumab
amgen,roche,takeda
['crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm']
this year s #asco22 plenary lba#1 goes to #crcsm
ph3 paradigm trial - dr t yoshino os benefit of 1l folfox-pani vs bev in l sided mcrc hr 0.84: pfs similar. orr
most provinces in still do not have funding for 1l egfr - hopefully this will now support access. 
Cancer Doctor, Professor. Researcher #GIcancer ????  @UBC @BCCancer @CCTG #Prez @CAMO #TEDxSpeaker #MedTwitter Tweets are my own